Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells.
Adaptive Immunity
Antigens, CD1
/ metabolism
Antigens, Neoplasm
/ immunology
Antineoplastic Agents, Immunological
/ pharmacology
Biological Products
/ pharmacology
Cross-Priming
Dendritic Cells
/ immunology
Glycoproteins
/ metabolism
Herpesvirus 1, Human
Humans
Immunotherapy
/ methods
Lymphocyte Activation
Melanoma
/ immunology
Myeloid Cells
/ immunology
Oncolytic Virotherapy
Phagocytosis
T-Lymphocytes
/ drug effects
BDCA-1
BDCA-3
Talimogene laherparepvec
cell therapy
immunotherapy
melanoma
myeloid dendritic cell
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
06
2021
accepted:
13
10
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
29
12
2021
Statut:
epublish
Résumé
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated by myeloid dendritic cells (myDC) that initiate an adaptive immune response. In this study we could demonstrate that T-VEC is non-toxic for human myDC. T-VEC and a T-VEC oncolysate of melanoma cell lines were able to mature human myDC. myDC were able to take up lysed melanoma cells and cross-present melanoma-derived tumor antigens to antigen-specific T cells. Our results support the possible role of myDC as mediators of an adaptive anti-tumor effect and intratumoral co-administration of T-VEC plus autologous myDC could be a complementary treatment option. A clinical trial that investigates this hypothesis is currently ongoing.
Identifiants
pubmed: 34777344
doi: 10.3389/fimmu.2021.733506
pmc: PMC8581672
doi:
Substances chimiques
Antigens, CD1
0
Antigens, Neoplasm
0
Antineoplastic Agents, Immunological
0
Biological Products
0
CD1C protein, human
0
Glycoproteins
0
talimogene laherparepvec
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
733506Informations de copyright
Copyright © 2021 Tijtgat, De Munck, Dufait, Schwarze, Van Riet, Franceschini, Breckpot, Aerts, Neyns and Tuyaerts.
Déclaration de conflit d'intérêts
BN and JS received non-financial support from Amgen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Nature. 2020 Aug;584(7822):624-629
pubmed: 32788723
EMBO Mol Med. 2010 Jun;2(6):193-5
pubmed: 20535746
Innate Immun. 2015 Aug;21(6):626-34
pubmed: 25749844
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Biomedicines. 2020 Mar 06;8(3):
pubmed: 32155856
Nat Commun. 2011 Nov 01;2:521
pubmed: 22045000
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Sci Transl Med. 2018 Dec 12;10(471):
pubmed: 30541787
J Immunol. 2010 Mar 15;184(6):2908-17
pubmed: 20164420
Pharmaceutics. 2020 Feb 15;12(2):
pubmed: 32075343
J Immunol. 2012 Sep 15;189(6):2735-45
pubmed: 22891284
Int J Mol Sci. 2020 Jul 21;21(14):
pubmed: 32708188
Front Microbiol. 2019 Nov 08;10:2611
pubmed: 31781083
Int J Oncol. 2002 Oct;21(4):685-94
pubmed: 12239606
Front Immunol. 2018 Sep 03;9:1923
pubmed: 30233565
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Int J Cancer. 2020 Jan 15;146(2):531-541
pubmed: 31584185
Gene Ther. 2020 Dec;27(12):537-544
pubmed: 31024072
J Immunol Methods. 2009 Mar 15;342(1-2):71-7
pubmed: 19135446
Front Immunol. 2019 Feb 12;10:9
pubmed: 30809220
Int J Cancer. 2003 Jan 1;103(1):73-83
pubmed: 12455056
Immunol Rev. 2009 Jan;227(1):234-47
pubmed: 19120488
Cancer Res. 2016 Nov 15;76(22):6747-6759
pubmed: 27680683
Cancer Immunol Immunother. 2005 Apr;54(4):372-82
pubmed: 15692847
Curr Med Chem. 2012;19(25):4239-46
pubmed: 22834814
Front Immunol. 2020 Jun 19;11:1267
pubmed: 32655564
J Leukoc Biol. 2013 Apr;93(4):599-609
pubmed: 23341538
Immunol Cell Biol. 2018 Apr;96(4):390-400
pubmed: 29344995
Semin Immunol. 2005 Aug;17(4):313-8
pubmed: 15955712
Oncoimmunology. 2019 Apr 7;8(7):1591875
pubmed: 31143509
Immunity. 2017 Mar 21;46(3):504-515
pubmed: 28329707
Clin Cancer Res. 2016 Mar 1;22(5):1048-54
pubmed: 26719429
J Immunother Cancer. 2019 Apr 18;7(1):109
pubmed: 30999964
Shock. 2006 Aug;26(2):174-9
pubmed: 16878026
Glia. 2011 Jan;59(1):58-67
pubmed: 20878770
Curr Protoc Immunol. 2013;Chapter 14:Unit 14.31.
pubmed: 23392636
Immunity. 2015 Jul 21;43(1):15-28
pubmed: 26200010
J Immunother Cancer. 2016 Sep 20;4:53
pubmed: 27660707
J Immunol Methods. 2019 Jul;470:27-32
pubmed: 31034881
Oncoimmunology. 2016 Aug 03;5(8):e1192739
pubmed: 27622063